These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15542803)

  • 1. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
    J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
    Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
    Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.